Cargando…
Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat
PURPOSE: Clinical guidelines recommend febuxostat as first-line pharmacologic urate-lowering therapy for patients with gout to achieve a goal serum uric acid (sUA) <6 mg/dL; however, little is known about other contributing factors. This study identified clinical characteristics of patients treat...
Autores principales: | Sheer, Richard, Null, Kyle D, Szymanski, Keith A, Sudharshan, Lavanya, Banovic, Jennifer, Pasquale, Margaret K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644566/ https://www.ncbi.nlm.nih.gov/pubmed/29066924 http://dx.doi.org/10.2147/CEOR.S139939 |
Ejemplares similares
-
Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010) -
Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013) -
Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008) -
Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010) -
Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)